Related Experiment Video
Updated: May 9, 2026

Size Matters: Measurement of Capsule Diameter in Cryptococcus neoformans
Published on: February 27, 2018
[Cryptococcosis: case reports, epidemiology and treatment options]
A Mischnik1, S Klein, K Tintelnot
1Department für Infektiologie, Medizinische Mikrobiologie und Hygiene, Universitätsklinikum Heidelberg, Germany. alexander.mischnik@med.uni-heidelberg.de
Cryptococcosis, a fungal infection often caused by Cryptococcus neoformans, is increasingly seen in non-HIV patients. Treatment varies based on infection severity and patient status, with specific antifungal therapies recommended.
Area of Science:
- Mycology
- Infectious Diseases
- Clinical Medicine
Background:
- Cryptococcosis, primarily caused by Cryptococcus neoformans, traditionally affects HIV-infected individuals.
- A shift in epidemiology shows increasing incidence in solid organ transplant recipients, patients with chronic organ diseases, and the immunocompetent.
Observation:
- Clinical manifestations range from localized respiratory and skin infections to disseminated meningoencephalitis.
- Hematogenous spread can lead to multi-organ involvement, presenting diverse clinical pictures.
- Rapid diagnosis is facilitated by sensitive laboratory tests, especially in disseminated cases.
Findings:
- Treatment strategies are tailored to the patient's underlying condition and organ involvement.
- Induction therapy for severe or disseminated infections involves amphotericin B plus 5-flucytosine.
- Fluconazole is indicated for non-severe localized infections and post-induction therapy; echinocandins are ineffective.
Implications:
- Understanding the changing epidemiology of cryptococcosis is crucial for timely diagnosis and management.
- Personalized therapeutic approaches are essential for optimizing outcomes in diverse patient populations.
- Further research into cryptococcosis in non-HIV populations may reveal novel diagnostic and therapeutic targets.
Related Concept Videos
Brain Abscess l: Introduction
Fungal Phylum Microsporidia
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia III: Complications and Assessment
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies. Common...